Naratriptan: Difference between revisions
Jump to navigation
Jump to search
Gerald Chi (talk | contribs) mNo edit summary |
Gerald Chi (talk | contribs) mNo edit summary |
||
| Line 13: | Line 13: | ||
==FDA Package Insert== | ==FDA Package Insert== | ||
''' | ''' [[Naratriptan indications and usage|Indications and Usage]]''' | ||
'''| [[Naratriptan dosage and administration|Dosage and Administration]]''' | '''| [[Naratriptan dosage and administration|Dosage and Administration]]''' | ||
'''| [[Naratriptan dosage forms and strengths|Dosage Forms and Strengths]]''' | '''| [[Naratriptan dosage forms and strengths|Dosage Forms and Strengths]]''' | ||
Revision as of 19:48, 3 February 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sheng Shi, M.D. [2]
For patient information about Naratriptan, click here
Synonyms / Brand Names:
Overview
Category
FDA Package Insert
Indications and Usage | Dosage and Administration | Dosage Forms and Strengths | Contraindications | Warnings and Precautions | Adverse Reactions | Drug Interactions | Use in Specific Populations | Overdosage | Description | Clinical Pharmacology | Nonclinical Toxicology | Clinical Studies | How Supplied/Storage and Handling | Patient Counseling Information | Labels and Packages